Author: Xconomy Online News

Making Sure Your Application Content Can be Accepted simply by Oculus

August 10th, 2022 Oculus headphones enable users to enjoy their favorite software in a virtual reality environment. Dependant upon the type of content material used, users can expect diverse experiences. Employing Oculus Creator Link, programmers can make certain that the app content is appropriate meant for the VR headset. Coders will use the knowledge they… Continue reading Making Sure Your Application Content Can be Accepted simply by Oculus

Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs

October 6th, 2020 Xconomy Boston —  Scientists at microbiome therapy developers often talk about the importance of community, how the bugs in our gut act in concert in addition to their individual roles. That’s important for microbiome health and for microbe-based therapies, says Emily Drabant Conley, CEO of startup Federation Bio. Conley’s company is developing therapies… Continue reading Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs

Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity

October 2nd, 2020 Xconomy National —  As the one-year anniversary of Bristol-Myers Squibb Company’s $74bn acquisition of Celgene Corporation approaches, Scrip spoke with chief medical officer Samit Hirawat about the big pharma’s achievements during a challenging period in which the COVID-19 pandemic threatened to derail clinical trials and a national spotlight on racial inequality shined… Continue reading Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity

Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy

September 15th, 2020 Xconomy Europe —  Cell therapy offers another option for addressing the most difficult blood cancer cases, but such treatments, which are engineered from a patient’s own immune cells, don’t yet work on solid tumors. Neogene Therapeutics is developing technology with the potential to bring cell therapies to solid tumors and it now… Continue reading Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy

Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More

July 31st, 2020 Xconomy National —  The biotech IPO market is buzzing but Cerevel Therapeutics is showing that there’s more than one path to the public markets. This week the neuroscience drug developer reached a deal to merge with publicly traded Arya Sciences Acquisition Corp II. If you’ve never heard of Arya (NASDAQ: ARYBU), it’s… Continue reading Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More

AlloVir’s IPO Raises $276M to Test Cell Therapies in Transplant Patients

July 30th, 2020 Xconomy Boston —  AlloVir is the latest biotech company to go public, raising about $276.3 million to pull its cell therapies off the shelf and run multiple clinical trials testing them in stem cell and organ transplant patients. On Thursday, Cambridge, MA-based AlloVir (NASDAQ: ALVR) priced its offering of 16.25 million shares at… Continue reading AlloVir’s IPO Raises $276M to Test Cell Therapies in Transplant Patients

Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test

July 29th, 2020 Xconomy National —  Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to evaluate its CancerSEEK test in a registrational study. Many cancers grow silently, and once malignant… Continue reading Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test

UCSD, 5 Diagnostic Makers Partner to Ramp COVID-19 Testing Capacity

March 20th, 2020 Xconomy San Diego —  A group of scientists and physicians at UC San Diego Health and the UCSD School of Medicine has arranged a partnership with five diagnostics markers that it says will bring the health system’s capacity to test for coronavirus to as many as 1,500 tests daily sometime in early… Continue reading UCSD, 5 Diagnostic Makers Partner to Ramp COVID-19 Testing Capacity

Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies

March 20th, 2020 Xconomy San Francisco —  Eureka Therapeutics, which has been developing methods to facilitate the development of cell therapies that can treat solid cancers, has raised $45 million to prove out its technologies in the clinic. To enhance its chances of success, the Emeryville, CA-based company has struck an agreement to work with… Continue reading Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies